Flexible, clinically adaptable, non-viral approaches to CAR TCR methodologies

DATE:  August 4, 2020

TIME:   8:00 am PDT, 11:00 am EDT

In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies that demonstrate the successful use of MaxCyte’s clinically validated, scalable electroporation system in the  pre-clinical and clinical scale engineering of resting and activated T cells using a mesothelin specific CARmRNA;  in the enhancement of  NK cell cytotoxicities against B cell malignancies using an antiCD19 CAR mRNA; in the transposon (Piggybac and Sleeping Beauty) based gene delivery for manufacture of CAR-T cells ; and finally in the gene editing of T cells for improving the efficacy of a TCR immunotherapy. In particular, during this webinar she will discuss how MaxCyte’s versatile ExPERT platform can enable the next-generation non-viral CAR T therapies including allogeneic, off-the-shelf modalities with the potential for enhanced effectiveness for refractory cancer.

Learning Objectives:

• Discover next-generation non-viral CAR approaches
• Compare detailed case studies of both autologous and allogeneic therapeutic solutions
• Assess the advantages of scalable non-viral approach throughout development and manufacturing process

Webinars will be available for unlimited on-demand viewing after live event.

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.